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1. Abstract 
Background: Patients with a clinical diagnosis or a family history of the two distinct 
entities Long QT syndrome (LQTS) and Hypertrophic cardiomyopathy (HCM) have 
a higher genetically based risk of serious arrhythmias and sudden cardiac death 
(SCD) than the general population. Living with this health threat may affect health 
status and cause anxiety.  The scientific development in the field of genetics has 
made it possible to offer these patients genetic investigation. However, in what way, 
this health threat affects the patients receiving genetic investigation and counseling is 
unknown. Patient- reported outcome measures may provide better understanding of 
these individuals’ situation, which is essential for the further development of 
improving quality of care in cardio-genetic counseling.  
Aims: The overall aim of this study was therefore to obtain more knowledge about 
the health status, levels of general anxiety and depression, and symptoms of heart-
focused anxiety in individuals receiving genetic investigation and counseling because 
of familial LQTS or familial HCM. The specific aims were; 
I) To investigate health status; in comparison to expected scores of Norwegian 
general population, and in relation to socio-demographic variables and clinical status; 
II) To investigate general anxiety, depression, and physical health, in comparison to 
expected scores of Norwegian general population or norm scores, in patients with 
familial LQTS as compared to patients with familial HCM, and in relation to the role 
of three distinct symptoms of heart-focused anxiety (avoidance, attention, and fear); 
XI 
and III) To explore if factors such as a family history of sudden cardiac death, patient 
knowing whether other relatives’ previously had undergone genetic testing, perceived 
general health, self-efficacy expectations, and satisfaction with genetic counseling 
(affective, instrumental, procedural) predict heart-focused anxiety up to one year after 
the genetic counseling. 
Methods: In a prospective multi-site study at three university hospitals in Norway 
during 2005-2007, all patients referred for medical genetic investigation and 
counseling because of  familial LQTS or familial HCM, over 17 years of age, and not 
previously genetically tested, were eligible to participate. Patients referred were 
family members and other appropriate relatives subsequently following the 
identification of a LQTS or HCM- causative mutation in an index case or individuals 
in whom a cardiologist had established or suspected a clinical diagnosis of LQTS or 
HCM. Among 175 patients asked, 127 (126) patients completed a questionnaire 
before the counseling session, and were asked to fill in questionnaires at several time 
points after the counseling session (right after, 4 weeks, 6 months, and 1 year after).  
The patient-reported outcomes were based on The SF-36 Health Survey, Hospital 
Anxiety and Depression Scale, Cardiac Anxiety Questionnaire, Bergen Genetic 
Counseling Self-efficacy Scale, Satisfaction with Genetic counseling, socio-
demographic and clinical variables.  Descriptive, comparative and prospective 
analyses were performed. Expected scores of Norwegian general population were 
calculated for health status, general anxiety and depression, for baseline comparisons. 
Multiple linear analyses were used to evaluate the relationship of socio-demographic, 
clinical variables and health status. Hierarchical regression analyses were used to 
XII 
assess the ability of three distinct symptoms of heart-focused anxiety (avoidance, 
attention, and fear) to predict levels of general anxiety, depression, and physical 
health. Mixed linear modelling (MLM) was used to investigate predictors and changes 
over time of the subscales of Cardiac Anxiety Questionnaire (CAQ); avoidance, 
attention, and fear. All predictors were entered into MLMs to assess both their main 
effects and their possible interaction with time.    
Results: I) Among the 127 study participants, 88 patients (69.3 %) were referred for 
familial LQTS, whereas 39 patients (30.7 %) were referred for familial HCM. 
Ninety-five patients (74.8 %) were family members and other appropriate relatives at 
genetic risk of LQTS or HCM, whereas individuals in whom a cardiologist had 
established a clinical diagnosis, 12 patients (9.4 %) were affected with LQTS and 20 
patients (15.7 %) were affected with HCM. Fifty-seven patients (44.9%) reported to 
have experienced a sudden cardiac death in a family member. Overall, patients 
reported significant poorer general health as compared to expected scores of the 
general population. Better health status scores were related to patients’ employment, 
higher education level, and referral to genetic counseling by a relative. Patients with a 
clinical diagnosis of HCM had markedly reduced health status as of compared to the 
general population, as compared to the patients at genetic risk of LQTS or HCM, and 
also compared to patients with a clinical diagnosis of LQTS. II) Overall, the patients 
reported significant higher levels of general anxiety as compared to expected scores. 
Patients at genetic risk for LQTS or HCM scored better on physical health as 
compared to expected scores, whereas the patients with a clinical diagnosis of LQTS 
or HCM showed poorer physical health as compared to expected scores. Compared to 
XIII 
the patients that were referred for familial LQTS, patients referred for familial HCM 
had poorer physical health and higher scores of heart-focused anxiety. Two distinct 
symptoms of heart-focused anxiety (avoidance and fear) were independently related 
to levels of general anxiety and depression, as well as to physical health (beyond the 
effect of gender, age, clinical diagnosis, and family history with a recent sudden 
cardiac death. III) A family history of sudden cardiac death in close relatives, 
uncertainty whether other relatives had genetic testing, poorer perceived health, low 
self-efficacy expectations before genetic counseling, and low procedural satisfaction 
immediately after the genetic counseling predicted higher levels of heart-focused 
anxiety up to one year after the counseling session (beyond the effect of questionnaire 
time points, age, gender, clinical diagnosis, and genetic test result). A mutation 
positive result predicted higher scores of cardio-protective avoidance 6 months after 
genetic counseling. 
Conclusions: Patients living with the health threat of serious arrhythmias and sudden 
cardiac death because of familial LQTS or familial HCM perceive their health to be 
poorer and have a higher general anxiety level compared to expected scores in the 
general population, before receiving genetic counseling. Distinct symptoms of heart-
focused anxiety such as the extent to which these individuals report cardio-protective 
avoidance and fear about heart sensations seem to influence their reporting of general 
anxiety, depression, and physical health. Predisposed individuals for heart-focused 
anxiety were patients who had experienced a close relative’s sudden cardiac death 
and patients uncertain whether other relatives previously had undergone genetic 
testing. However, satisfaction with the procedural parts of genetic counseling was 
XIV 
predictive of decreased levels of heart-focused anxiety. The resources of greatest 
prognostic importance to prevent heart-focused anxiety may be the way individuals 
perceive their general health and their self-efficacy expectations. The present findings 
indicate that individuals undergoing genetic investigation and counseling for familial 
LQTS or familial HCM are vulnerable in both health-related and psychological 
domains before genetic counseling, and may benefit from a closer collaboration 
between the genetic counselor and the cardiologist addressing their experience of 
cardiac symptoms to a greater extent. 
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1. Introduction 
International guidelines for management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death (ACC/AHA/ESC 2006) emphasize the 
importance of genetic testing in Long QT syndrome (LQTS) families and the 
usefulness of testing in families with Hypertrophic cardiomyopathy (HCM) (Zipes et 
al, 2006). LQTS is a channelopathy (Kramer & Zimetbaum, 2011) and HCM is a 
sarcomere disorder (Watkins, et al., 2011). Common for the patients with familial 
LQTS and familial HCM is a genetically based increased risk for serious arrhythmias. 
Both patients with a clinical diagnosis, as well as their relatives who are at genetic risk 
of developing the disease, therefore live with the threat of a premature sudden cardiac 
death (Maron, 2003; Maron, 2009; Vincent, 2005). Living with such a health threat 
may have big consequences for the health and wellbeing of these individuals. 
 
In health sciences the concepts of health status, general anxiety and depression, and 
heart-focused anxiety are often researched. These concepts may also be particularly 
relevant to study in individuals who receive genetic investigation and counseling 
because of familial LQTS or familial HCM.  Firstly, the clinical diagnosis of LQTS or 
the clinical diagnosis of HCM may by themselves give considerable discomfort, when 
patients experience syncope, palpitations, or other debilitating symptoms. In addition, 
emotional reactions are likely, since the risks of cardiac symptoms are so immediate 
and possibly fatal. Secondly, LQTS and HCM are autosomal dominant disorders, 
which mean children, siblings and parents of a mutation carrier have a 50 percent risk 
of also being affected, thus they are also living with risk of serious cardiac symptoms. 
The penetrance (likelihood for actually developing the disease) is however varying, 
which leads to uncertainty of ever experiencing clinical symptoms of the disorder. 
Thirdly, identifying individuals with a high risk implies medication and life-style 
advice to prevent sudden cardiac death. Since the penetrance is not 100%, no-one will 
ever know whether the medication which may have side-effects was necessary. 
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Moreover, relevant health advice implies that excessive physical activity should be 
avoided as well as prolonged ‘stress’. Lastly, individual differences may potentially 
influence on how patients adapt to living with familial cardiac disorders.  
 
Patient perspective has become essential for quality of care. While the research 
concerning LQTS and HCM has focused on genes, mutations, morbidity and 
mortality, very little research has been based on patient-reported outcomes of adult 
persons undergoing the process of genetic investigation and counseling for familial 
LQTS or familial HCM. The impact of measuring patient-reported outcomes may 
pertain to provision of important understanding of patients physical or psychological 
vulnerabilities that otherwise might be overlooked. Further it may give information on 
disease progression, results of interventions, and establishing a more common 
understanding between the patient and the health-care provider (Valderas & Alonso, 
2008). 
 
The aim of genetic counseling is “helping people understand and adapt to the medical, 
psychological and familial implications of genetic contributions to disease”. The 
rapidly developing gene technology has made it possible to identify individuals with 
an increased risk for familial disorders such as LQTS or HCM. This has resulted in 
increasing needs to develop health communications, counseling services, and 
interventions for helping patients to cope with genetic risk. Knowledge based on 
patients’ perspective is essential for the continuation of developing cardio-genetic 
counseling. Thus, the focus of this thesis will be from the patient perspective using 
patient-reported outcome measures that reflect health status, levels of general anxiety 
and depression, as well as symptoms of heart-focused anxiety. There will also be a 
focus on patients’ self-efficacy expectations and satisfaction with genetic counseling. 
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One thing is for certain, these concepts are close to the heart in more ways than one. 
Not only is it the physical side of a hearth that beats in a rhythm, but it is also all the 
emotional components we attach to it, and that also may affect the physical heart.  
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2. Familial long QT syndrome and familial 
hypertrophic cardiomyopathy 
2.1 Long QT syndrome  - a channelopathy  
LQTS is a congenital disorder characterized by a prolongation of the QT interval on 
electrocardiogram (ECG) and an increased risk of ventricular arrhythmia e.g. 
Torsades-de Pointes (TdP), associated with increased risk for syncope, cardiac arrest, 
or sudden cardiac death, especially in young individuals (Vincent, 2005). The 
diagnosis is based on the measurement of the QT-interval in ECG, clinical history, 
and/or a family history of LQTS and sudden cardiac death (Schwartz, 2006; Crotti et 
al., 2008). Diagnostic criteria based on the characteristic features of LQTS are shown 
in table 2.1. 
 
Molecular genetic investigation has become an important supplement in the 
diagnostics, after identification in the mid-nineties of the first three LQTS genes 
KCNQ1, KCNH2 and SCN5A associated with the most common phenotypes of 
LQT1, LQT2 and LQT3 (Wang et al., 1995; Curran et al., 1995; Wang et al., 1996). 
The type of LQTS influences clinical course, in that most cardiac events are triggered 
by exercise and stress in LQT1, by emotional stress such as auditory stimuli in LQT2, 
while most cardiac events happen under sleep or rest for LQT3 (Schwartz et al., 2001). 
The lethality of cardiac events is suspected to be in the range from 2 to 20 % (Zareba 
et al., 1998). LQTS may be inherited as an autosomal dominant trait with either full or 
reduced penetrance (Romano-Ward syndrome) (Ward, 1964; Romano, Gemme & 
Pongiglione, 1963; Romano, 1965), or as an autosomal recessive trait (Jervell-Lange-
Nielsen syndrome with congenital deafness)(Schwartz et al., 2006; Jervell & Lange-
Nielsen, 1957). Mutation carriers may have symptoms or have prolonged QT-interval 
in ECG, but carriers with neither symptoms nor prolonged QT-interval may also have 
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an increased risk for sudden cardiac death, making molecular testing essential for 
initiating medication (-blockers) and life-style advice for asymptomatic mutation 
carriers.  Reported prevalence varies from 1/10 000 to 1/2500 (Crotti et al., 2008). In 
some parts of the world it is estimated to be higher due to founder mutations which are 
also the case in Norway (Berge et al., 2008). 
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Table 2.1 Diagnostic criteria for Long QT syndrome (LQTS) according to EKG 
findings, clinical history, and family history 
   Points
ELECTROCARDIOGRAPHIC 
FINDINGS # 
   
A QTc^ > 480 ms  
460 – 470 ms  
450 – 459 
(male) ms 
3 
2 
1
B Torsade de pointes *  2
C T wave alternans  1
D Notched t wave in 3 leads  1
E Low heart rate for age @  0.5
CLINICAL HISTORY   
A Syncope * With stress  
Without stress 
2 
1
B Congenital deafness  0.5
FAMILY HISTORY $   
A Family members with definite LQTS  1
B Unexplained sudden cardiac death below 
age 30 among immediate family 
members 
 0.5
Source: Crotti et al. (2008). Congenital long QT syndrome. Orphanet Journal of Rare Diseases, 3:18. 
http://www.ojrd.com/content/3/1/18 
# In the absence of medications or disorders known to affect these electrocardiographic features 
^ QTc calculated by Bazett's formula where QTc = QT/RR 
* Mutually exclusive 
@ Resting heart rate below the 2nd percentile for age 
$ The same family member cannot be counted in A and B 
SCORE:   1 point = low probability of LQTS, > 1 to 3 points = intermediate probability of LQTS,  
3.5 points = high probability of LQTS 
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2.2 Hypertrophic cardiomyopathy  - a sarcomere disease 
HCM is an excessive thickening of the heart muscle in the left and/or right ventricle 
(Maron, 2002; Watkins et al., 2011) (Fig. 2.1), and it is defined by the presence of this 
increased ventricular wall thickness or mass, having ruled out hypertension and valve 
disease (Elliott et al., 2008).  
 
Figure 2.1 Difference between a normal heart and hypertrophic cardiomyopathy. 
 
Myocyte disarray and fibrosis is typical features (Maron, 2002; Watkins et al., 2011).  
The symptoms are dyspnea, palpitations, syncope/near syncope’s, chest pains and 
arrhythmias. Like in LQTS, sudden cardiac death can present as first manifestation of 
the disorder (Maron, 2002). Diagnosis is made with 2-dimensional echocardiography, 
and the cardiac disorder may be suspected because of a heart murmur, abnormal ECG, 
symptoms and a positive family history (Maron, 2002).  Molecular screening is 
available. The genetic traits are mainly autosomal dominant with varying penetrance, 
but also autosomal recessive, X-linked, and sporadic (5%). Established symptomatic 
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treatment exists, such as medications, pacemaker, intracardial defibrillator (ICD), 
surgery, and advice for daily living. HCM is the most prevalent inherited cardiac 
disorder, affecting 1/500. Overall, the annual mortality rate from HCM is estimated to 
be 1 to 5 % (Maron, 2002).  
 
2.3 Common characteristics of Long QT syndrome and 
Hypertrophic cardiomyopathy 
Although, LQTS is a channelopathy (Goldenberg & Moss, 2008) and HCM is a 
sarcomere disease (Watkins et al., 2011), genetic investigation and counseling follows 
the same protocol for both familial cardiac disorders. This is based on the two 
disorders many common characteristics in the genetic setting. In addition, both LQTS 
and HCM patients face a serious health threat, serious symptoms, the threat of sudden 
cardiac death, and the possibility that their children have inherited the same disorder. 
Both entities have incomplete penetrance and variable expression. There are great 
uncertainties regarding symptoms, management and prevention, and both cardiac 
disorders require adjustments of life style and avoidance of triggers. The complexities 
in managing these patients and their relatives at risk, calls for clinicians with 
considerable experience and knowledge of the disorders, and guidelines that reflect 
international expert opinion (Garratt et al., 2010).   
2.4 International guidelines for management of patients with 
ventricular arrhythmias and the prevention of sudden 
cardiac death 
International guidelines specifically address familial cardiac disorders such as LQTS 
and HCM with regards to management and the prevention of sudden cardiac death 
(Zipes et al., 2006). Sudden cardiac death (SCD) is according to the Task Force of 
Sudden Cardiac Death, European society of cardiology defined as “Natural, non 
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traumatic death due to cardiac causes, heralded by abrupt loss of consciousness within 
one hour of the onset of symptoms. Pre-existing heart-disease may have been known 
to be present, but the time and mode of death are unexpected” (Priori et al., 2002). 
LQTS is responsible for a significant proportion of SCDs in young people without 
structural heart disease (Berul, 2008). In young people and in athletes the most 
common cause of death in the United States has been reported to be HCM (Maron, 
2009; Maron, 2003). In Norway there is no available information at present of the 
incidence of sudden cardiac death due to familial LQTS or familial HCM. It is 
expected to be at least similar to international numbers.   
 
The question if a sudden cardiac death or an episode of aborted cardiac arrest was 
caused by a familial disorder such as LQTS or HCM, and the consequences that other 
relatives may be at risk, are a concern that adds to the trauma for the families that 
experience this. According to the guidelines, lifestyle changes such as avoidance of 
competitive sports activity are recommended, for both LQTS and HCM patients. Beta 
blockade is recommended for patients with a prolonged QT interval and is part of the 
management of HCM.  Implantation of ICD remains controversial however 
recommended  for LQTS patients with previous cardiac arrests and HCM patients who 
have sustained ventricular tachycardy and /or ventricular fibrillation, receiving optimal 
medical therapy and have prospects of good functional status for over 1 year. The 
guidelines emphasize the importance of genetic testing in LQTS families and the 
usefulness of testing in families with HCM , thus genetic investigation and counseling 
is warranted in these families (Zipes et al., 2006).  
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3. Genetic investigation and counseling of familial 
Long QT syndrome and familial hypertrophic 
cardiomyopathy 
3.1 Genetic investigation  
Today, individuals with an increased risk of developing life-threatening arrhythmias 
because of LQTS or HCM can be identified with a genetic investigation. Expert 
Consensus Recommendations has been developed for the use and role of genetic 
testing for potentially heritable cardiac conditions (Ackerman et al., 2011). A 
summary of expert consensus recommendations for the state of genetic testing for both 
LQTS and HCM is shown in table 3.1.  
 
The genetic investigations of familial LQTS or familial HCM comprise mainly two 
forms of genetic testing, diagnostic and predictive testing. Diagnostic testing involves 
confirming a suspected or evident clinical diagnosis in an index case, whereas 
predictive testing is used to determine whether a patient with a proven gene mutation 
in a close family member has the gene mutation that involves risk for future disease.  
 
Mutations in genes encoding cardiac potassium or sodium ion channels can be found 
in two-thirds of patients affected with LQTS (Schwartz et al., 2001; Splawski et al.,  
2000; Zareba et al., 1998). An overview over molecular genetics of LQTS in the 
clinical setting is shown in table 3.2.  
 
Predictive genetic testing is a valuable tool to identify at-risk individuals by “cascade 
testing” (genetic testing of a mutation carrier’s first degree relatives) in the families 
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that are affected with LQTS. This is especially important, because predictive genetic 
testing is the only way to rule out LQTS in such family members because of the 
variable penetrance and expression of the disorder. However, because diagnostic 
genetic testing identifies a disease causing mutation in approximately 75% to 80 % of 
clinically affected LQTS patients (Schwartz, 2006; Ackerman et al., 2011), a negative 
diagnostic genetic test cannot completely exclude the diagnosis of LQTS by itself. 
Rare variants of uncertain significance (VUS) in the LQT1-3 genes also complicate 
the interpretation of gene test results (Ackerman et al., 2011). Therefore, clinical 
diagnostic genetic testing should not be performed on index cases without cardiology 
consultation according to the recommendations (Ackerman et al., 2011).  
Genetic investigation has also become available in families with HCM, where 
dominant mutations in sarcomeric protein genes are associated with a high risk of 
sudden cardiac death (Bos et al., 2009). The molecular genetics of HCM is shown in 
table 3.3. Mutations in 14 genes that encode different proteins of the cardiac sarcomere 
cause the autosomal dominant form of HCM. Two of the genes predominate; The 
MYBPC3 (myosin-binding protein C) and MYH7 (-myosin heavy chain) (Bos et al., 
2009). In HCM patients, mutations in one of those genes can be found in 30-80 % 
depending on case ascertainment (Andersen et al., 2009; Maron et al., 2007; Van 
Driest et al., 2005), thus more limitations apply as compared to LQTS diagnostic 
testing in excluding a HCM diagnosis. However diagnostic genetic testing is 
recommended for patients with a firm clinical diagnosis of HCM, first of all because it 
may benefit family members and other relatives. Furthermore, predictive genetic 
testing of patients with a proven gene mutation in a close family member is 
recommended over clinical screening because ECG or echocardiographic 
abnormalities may be absent or subtle, or develop at a later stage (Ackerman et al., 
2011).  
 
12 
 
 
Table 3.1 Summary of Expert Consensus Recommendations* 
State of genetic testing for Long QT syndrome (LQTS) 
  Class I (is recommended)  
 Comprehensive or LQTS1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic 
testing (diagnostic) is recommended for any patient in whom a cardiologist has 
established a strong clinical index of suspicion for LQTS based on examination of the 
patient’s clinical history, family history, and expressed electrocardiographic (resting 
12-lead ECGs and/or provocative stress testing with exercise or catecholamine 
infusion) phenotype. 
 Comprehensive or LQTS1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic 
testing (diagnostic) is recommended for any asymptomatic patient with QT 
prolongation in the absence of other clinical conditions that might prolong the QT 
interval (such as electrolyte abnormalities, hypertrophy, bundle branch block etc., i.e., 
otherwise idiopathic) on serial 12-lead ECGs defined as QTc> 480 ms (prepuberty) or 
> 500 ms (adults). 
 Mutation-specific genetic testing (predictive) is recommended for family members 
and other appropriate relatives subsequently following the identification of a LQTS-
causative mutation in an index case.  
  Class II (may be considered)  
 Comprehensive or LQTS1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic 
testing (diagnostic) may be considered for any asymptomatic patient with otherwise 
idiopathic QTc values >460 ms (prepuberty) or > 480 ms (adults) on serial 12-lead 
ECGs. 
State of genetic testing for Hypertrophic cardiomyopathy* 
  Class I (is recommended)  
 Comprehensive or targeted (MYBPC3, MYH7, TNNI3, TNNT2, TPM1) HCM genetic 
testing (diagnostic) is recommended for any patient in whom a cardiologist has 
established a clinical diagnosis of HCM based on examination of the patient’s clinical 
history, family history, and electrocardiography/ echocardiography phenotype. 
 Mutation-specific genetic testing (predictive) is recommended for family members 
and appropriate relatives following the identification of the HCM-causative mutation in 
an index case.  
* Source:  Ackerman et al. (2011). HRS/EHRA expert consensus statement on the state of genetic 
testing for the channelopathies and cardiomyopathies: this document was developed as a 
partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm 
Association (EHRA). Europace., 13, 1077-1109. 
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Table 3.2. Molecular genetics of Long QT syndrome (LQTS)*† 
Locus 
Name 
Gene 
Symbol 
Chromosomal 
Locus Protein Name 
% of LQTS 
attributed to 
mutations in this 
gene 
LQT1 KCNQ1 11p15.5 Potassium voltage-gated 
channel subfamily KQT 
member 1 
58% 
LQT2 KCNH2 7q35-q36 Potassium voltage-gated 
channel subfamily H 
member 2 
35% 
LQT3 SCN5A 3p21 Sodium channel protein 
type 5 subunit alpha 
5% 
LQT5 KCNE1 21q22.1-q22.2 Potassium voltage-gated 
channel subfamily E 
member 1 
1% 
LQT6 KCNE2 21q22.1 Potassium voltage-gated 
channel subfamily E 
member 2  
1% 
* http://www.ncbi.nlm.nih.gov/books/NBK1129/ accessed 6 June 2011, updated 20 October 2011, 
publisher; National Center for Biotechnology information (NCB1) 
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Table 3.3  Molecular genetics of Hypertrophic cardiomyopathy (HCM)*† 
Locus 
Name 
Gene 
Symbol 
Chromosomal 
Locus Protein Name 
% of HCM attributed 
to mutations in this 
gene 
CMH1 MYH7 14q12 Potassium voltage-gated 
channel subfamily H 
member 2 
35% 
CMH4 MYBPC3 11p11.2 Myosin-binding protein 
C, cardiac-type 
40% 
CMH2 TNNT2 1q32 Troponin T, cardiac 
muscle 
5% 
CMH7 TNNI3 19q13.4 Troponin I, cardiac 
muscle 
5% 
CMH3 TPM1 15q22.1 Tropomyosin 1 alpha 
chain 
2% 
CMH10 MYL2 12q23-q24.3 Myosin regulatory light 
chain 2, 
ventricular/cardiac muscle 
isoform 
Unknown 
CMH8 MYL3 3p Myosin light polypeptide 
3 
1% 
 ACTC1 15q14 Actin, alpha cardiac 
muscle 
Unknown 
 CSRP3 11p15.1 Cysteine and glycine-rich 
protein 3, muscle LIM 
protein 
Unknown  
CMH9 TTN 2q31 Titin  
 ACTN2 1q42-q43 Alpha-actinin-2 Unknown 
TNNC1  3p21.3-p14.3   
* http://www.ncbi.nlm.nih.gov/books/NBK1768/ accessed 6 July 2011, updated 20 October, 
publisher; National Center for Biotechnology information (NCB1) 
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3.2 Genetic counseling 
The new possibilities we have today through technology and in dealing with familial 
cardiac disorders are reflected in the definition of genetic counseling from the National 
Society of Genetic Counselors (NSGC)(Resta et al., 2006). 
 
“Genetic counseling is the process of helping people understand and adapt to the 
medical, psychological and familial implications of genetic contributions to 
disease. This process integrates:  
 
 Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence.  
 Education about inheritance, testing, management, prevention, resources and 
research.  
 Counseling to promote informed choices and adaptation to the risk or 
condition”  
 
The definition emphasize genetic counseling as a specialist field with the goal of 
communicating inherited risk information that is based on genetic investigation 
(Demarco et al., 2004), in a manner that can help the individual to adaptive coping 
processes. The practice and procedure of genetic investigation as well as the 
counseling to patients with familial LQTS or familial HCM is still under development, 
in order to be able to reach this important goal. 
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3.3 Current practice of genetic investigation, counseling and 
the Norwegian legislation 
In Norway, the Act relating to the application of biotechnology in human medicine 
(Biotechnology act of 1994, and later Act of 2003, see Appendix) regulates clinical 
genetic activities first of all by paragraph 5-2 that states that “Genetic testing shall only 
be carried out for medical purposes if it has a diagnostic or therapeutic objective” 
(2003). 
 
There has been a long tradition for genetic counseling that started already several 
decades before the first Biotechnology Act, however the current practice of genetic 
investigations in families with LQTS have only existed since approximately 2001 
(Hamang et al., 2009), whereas HCM genetic investigations started approximately in 
2004. The molecular genetic testing has been performed at Rikshospitalet in Oslo 
(Haugaa et al., 2005), whereas the genetic counseling has been conducted at the main 
regional tertiary hospitals throughout the country.  
 
Today, the genetic investigation and counseling is mainly performed by a team of 
medical geneticists and genetic counselors. However, cardiologists also increasingly 
conduct diagnostic genetic testing as part of their clinical investigation in determining 
a patient’s diagnosis. Collaboration between the heart departments and the specialized 
cardio-genetic clinics is essential because of the importance of establishing firm 
clinical diagnoses of index-cases (Ackerman et al., 2011).  
 
In contrast to diagnostic genetic testing that can be performed without prior genetic 
counseling, the current Act regulates predictive genetic testing more strictly.  In 
addition to the demand for a diagnostic or therapeutic objective for carrying out 
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testing, the law state that genetic counseling shall be given before, during, and after 
predictive genetic testing of the person. In cases where a child under 16 years is 
predictively tested, the child’s parents, or other person who has parental responsibility 
should receive genetic counseling. Furthermore, written consent must be obtained of 
the counselees. And finally, “unless the test can detect a condition for which treatment 
may prevent or reduce damage to a child’s health”, testing children under 16 years of 
age is prohibited.  However, since both LQTS and HCM can affect children and 
dangerous symptoms can be prevented, current practice performs predictive genetic 
testing on children.  
3.4 Procedure of the genetic counseling sessions 
Before the genetic counseling session the patient information and family history is 
verified in medical records, autopsy reports, and other relevant documents which are 
collected after approval of the patient and relatives involved. Apart from verifying 
diagnosis in medical records/autopsy reports etc, important parts of the genetic 
investigation are collecting information pertaining to previous genetic testing, 
incidence of the disease in the family, onset of disease in relatives with relevant 
diagnosis/symptoms, and exploring circumstances around sudden cardiac deaths in the 
family.  
 
Typically the genetic counseling is offered over the course of two-three sessions. After 
a medical genetic review of the family history and available information, one pre-test 
session is offered to provide the patient and family with information (see table 3.4) and 
one disclosure session where the genetic test result is disclosed to the patient. Subjects 
discussed in the pre-test session, include prevalence, symptoms, clinical findings, 
prognosis, recurrence risk, genes, mutations, and treatment, as well as questions 
regarding genetic testing. Evaluation of the genetic risk is based upon family history, 
symptoms, clinical findings, and age of onset. Information from a genetic test is only a 
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supplement to the risk assessment today, since in many families, it is currently 
impossible to detect a gene mutation (see above). However once a gene mutation is 
identified in a patient, genetic testing of other relatives is possible. 
 
In the genetic counseling session the genetic counselor aims to individualize the 
information based on the patient’s need of information and support. Identification of a 
disease causing mutation may have implications for issues such as profession, 
education, driver license and insurance. Therefore, it may be relevant to discuss these 
matters as well. 
 
Apart from that the patient is informed of the genetic test result and its implications in 
the disclosure session, important information from the pre-test session is repeated. In 
addition, the identification of other at-risk relatives is conducted together with the 
patient.  
 
Patients that are proven mutation carriers and patients with inconclusive results are 
offered subsequent consultations and are referred for cardiac investigations, controls 
and follow up, whereas patients that have tested negative for the specific family 
mutation has no need for further cardiological follow up, from a medical standpoint.  
 
The literature raises a number of ethical questions and emphasizes psychological 
issues that one should be aware of with regard to genetic testing and management of 
patients at risk of familial cardiac disorders (Aatre & Day, 2011; Charron et al., 2002; 
Mularczyk et al.,; van Langen et al., 2004). However, this literature has mainly been 
based on information from the clinician’s perspective, and more specific knowledge 
about the patients’ is needed.  Apart from that these patients face the risk of life 
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threatening events and are subjected to genetic testing, they may also experience 
symptoms, disability and reduced wellbeing as a result of living with familial LQTS or 
HCM. Patient perspectives of their health have not only become important in health 
research, but essential knowledge to achieving high quality care (Black & Jenkinson, 
2009). This is further outlined below. 
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Table 3.4 Subject to be covered according to protocol for pre-test genetic counseling 
session of patients with familial LQTS or familial HCM 
 
 Review of personal and family medical history (symptoms, clinical diagnosis, 
known heart-disorders in the family, anyone who died suddenly) 
 Identification of a possible genetic risk (family history of a certain cardiac disorder 
or identification of a definite disease-causing mutation in an index case) 
 Explanation about the nature of the familial disorder (incidence, age at onset, 
symptoms) 
 Explanation of possible inheritance patterns (autosomal dominant/recessive) 
 Review of appropriate testing options and its consequences (what does a test result 
mean, and implications of disclosure of test result.) 
 Discussion of prevention strategies and disease management (prophylactic 
treatment, avoidance of triggers) 
 Provision of genetic-related information and suggestion of reliable resources 
(patient information, online patients websites) 
 Counseling to promote informed choices and adaptation to the risk or the disease 
 The opportunity of molecular genetic testing if appropriate 
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4. Patient-reported outcomes in patients undergoing 
genetic investigation and counseling for familial 
Long QT syndrome and Hypertrophic 
cardiomyopathy 
In contrast to measured physiological values, mortality and morbidity, patient-reported 
outcome measures assesses the patients’ perspective of their own functional status and 
wellbeing (Dawson et al., 2010). The impact of measuring patient-reported outcomes 
may pertain to provision of important understanding of patients physical or 
psychological vulnerabilities that otherwise might be overlooked. Further it may give 
information on disease progression and results of interventions, and establishing a 
more common understanding between the patient himself and the health-care provider 
(Valderas & Alonso, 2008).  
 
The patient-reported outcome measures may either be generic (measuring patients 
perception of their general health and wellbeing), disease-specific (measuring patients 
perception of their health and wellbeing in relation to specific conditions) (Dawson et 
al., 2010), or dimension-specific (exploring particular domains to greater depth) 
(Fayers & Machin, 2007a).  The term patient- reported outcome indicates interest in a 
whole range of outcomes (Fayers & Machin, 2007; Doward & McKenna, 2004). The 
outcomes chosen for the present study were health status, general anxiety, depression, 
physical health, heart-focused anxiety, general health perceptions, self-efficacy, and 
satisfaction with genetic counseling. 
 
A literature search in PubMed of journal articles published up to present time (October 
2011) comprising either of the following search words in title or abstract; health status, 
quality of life, physical health, mental health, anxiety, depression, psychological 
distress, psychological, emotional distress, coping, self-efficacy, or satisfaction, and 
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comprising either Long QT syndrome, Hypertrophic cardiomyopathy or hereditary 
heart disease, and either hereditary, familial, family history, inherited or genetic in any 
field retrieved 86 articles. Only 17 of these articles present data on patient-reported 
outcomes from patients with familial LQTS or familial HCM, and only three of these 
were published before the present study was initiated, one of the latter was in Dutch 
language. A review of the remaining 16 patient-reported outcome studies (with regard 
to research question asked, sample characteristics, type of design, methods of 
measuring variables and key findings) is presented in Table 4.1.   
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4.1 Health status 
The World Health Organization (WHO, 1948) defines health to be, not only absence 
of disease, but a “state of complete physical, mental and social well-being”. There is 
general consensus that health consists of these three aspects of well-being, however 
there are big variations across studies as to how to define health, and most 
investigators avoid the definitions and let the health domains speak for themselves 
(Fayers & Machin, 2007).   
 
The present study chose to include both physical and mental health domains as 
measured by SF-36 Health Survey (Ware, Jr. & Gandek, 1998). This measure has been 
used extensively in health research. In accordance with WHOs definition of health, 
SF-36 measures not only health functioning but also well-being. Health functioning is 
according to SF-36 literature, the extent to which health limits the patient in physical, 
social and role activities. Perceived wellbeing is defined as frequency and intensity of 
feeling states including general mental health, bodily pain and vitality. In addition, 
patient perception of health in general is included in the health concept. Including 
perceived general health may be a strength, given critical arguments of that health 
status questionnaires mainly assess domains that are of clinical importance, but that 
may not be the concern of the patient (Doward & McKenna, 2004). For example no 
major differences were found in physical and mental health domains of children at risk 
of inherited cardiac disorders compared to peers (Smets et al., 2008). However, other 
research has found that children in this situation may feel a loss of control, worries 
about dying, and frustrations of being different (Meulenkamp et al., 2008; Giuffre et 
al., 2008; Meulenkamp et al., 2008), all of which most likely will affect the general 
perception of health. 
 
30 
 
Previous research has shown that several clinical variables may affect health in 
patients with familial cardiac disorders. With regard to the adult population clinically 
affected with LQTS or HCM, health status has been measured quantitatively in HCM 
patients (Christiaans et al., 2009b; Cox et al., 1997), and has been described 
qualitatively in LQTS patients (Andersen et al., 2008). The results from these 
investigations showed that HCM patients had major impairments in both physical and 
mental health domains. LQTS patients experienced daily limitations such as having to 
rest and not being able to work because of symptoms of fatigue, exhaustion, 
palpitations and headaches (Andersen et al., 2008).  
 
Health status has been strongly related to symptom patterns, although not consistently. 
In one of the studies of HCM patients, both affected and unaffected patients were 
included, comparing patient-reported outcomes in patients with clinical diagnosis and 
patients at genetic risk for HCM in terms of predictors of physical health, mental 
health and psychological distress (Christiaans et al., 2009b). The presence of a clinical 
diagnosis or HCM related symptoms were strongly related to impaired physical health. 
However, for both groups perceptions of risk and carrier-ship (perceived risk of 
sudden cardiac death, or belief in serious consequences, or symptoms) greatly affected 
physical and mental health as well as anxiety and depression levels. Thus there is a 
need to further explore the health status in patients with familial cardiac disorders. 
 
4.2 General anxiety and depression 
General anxiety is most often associated with the emotion of fear, involving feelings 
of tension, worry, apprehension, and dread for something perceived as threatening in 
the future (Stein & Hollander, 2002), while depression is usually described as an 
emotion of sadness, with feelings of sorrow, hopelessness, gloom, lack of energy and 
adhedonia (Watson et al., 1995). Standard classification of mental disorders is 
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described and specified in the International Classification of Diseases ICD-10 (World 
Health Organisation., 1992), or the Diagnostic and Statistical Manual of Mental 
Disorders of the American Psychiatric Association (DSM-IV) (American Psychiatric 
Association, 1987), which views anxiety and depression as discrete 
psychopathological disorders. In contrast to this categorical approach, the dimensional 
approach views symptoms of anxiety and depression as normal responses to demands 
and threats measured on a continuum from absence to maximum intensity (Bjelland & 
Dahl, 2008). In the present study the Hospital Anxiety and Depression scale dictates a 
categorical approach (Zigmond & Snaith, 1983).  
 
Addressing the psychological consequences of LQTS predictive testing in a 
longitudinal study, general anxiety and depression levels were found to be close to that 
of the normal population within 18 months after testing (Hendriks et al., 2008).  
Depression levels were lower among those who were more satisfied with follow up, 
thus HCM patients that attend follow up seem better adjusted and have less worry 
(Cox et al., 1997; Ingles et al., 2008). How general anxiety and depression levels 
compares to expected scores of the general population should be further investigated 
in patients referred to genetic investigation and counseling for familial LQTS or 
familial HCM. Further there is a need to investigate whether general anxiety and 
depression differ between LQTS and HCM patient groups. 
4.3 Heart-focused anxiety  
In this study heart-focused anxiety is defined as the specific fear of cardiac-related 
stimuli and sensation based on the perception that symptoms will be harmful, causing 
i.e. serious arrhythmias or sudden cardiac death (Eifert et al., 2000a). 
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Responding to cardiac-related stimuli and sensations with cardio-protective avoidance, 
heart-focused attention, and fear about heart sensations is associated with the presence 
of heart-focused anxiety (Eifert, 2000a). The concept is identified as a psychological 
process variable related to heightened anxiety levels (Eifert et al., 2000b). Heart-
focused anxiety was originally identified as a psychological problem closely related to 
anxiety sensitivity and “cardiophobia” among patients without actual heart disease 
(Eifert, 1992; Eifert & Forsyth, 1996a; Eifert et al., 1996b), but has also been shown to 
be a relevant psychological variable to study in patients with actual heart-disease 
(Hoyer et al., 2008). Based on that levels of anxiety increase among patients with 
actual cardiac disease after receiving a diagnosis, and that physical healthy patients 
can be as concerned as patients with a justifiable concern about heart disease, previous 
findings indicate that heart-focused anxiety also may be an individual difference factor 
(Eifert et al., 2000b; Eifert, 1992).  
A conceptual and clinical review of heart-focused anxiety and chest pain suggest that 
responding fearful to cardiac-related stimuli and sensations may be part of a vicious 
circle that not only creates even higher levels of cardio-protective avoidance, heart-
focused attention, and fear about heart sensations, but also may contribute to greater 
levels of perceived pain, disability, and future episodes of elevated anxiety or panic 
(Eifert, 2000b). Therefore it is necessary to find out how symptoms of heart-focused 
anxiety relate to general anxiety, depression and physical health in the present patient-
group.  
 
Heart-focused anxiety may be explained by previous learning conditions relating to 
separation issues and cardiac disease, psychological vulnerability, negative events, as 
well as genetic and acquired biological vulnerability factors (Eifert, 1992).  
 
LQTS patients participating in a qualitative study reported daily limitations and 
anxiety because of their disorder (Andersen et al., 2008). Perceived symptoms or 
33 
 
family members worrying about them caused them to avoid certain activities. 
Uncertainty, unresolved emotions and worries about other relatives at risk caused 
anxiety (Andersen et al., 2008). A study showed that self-reported emotional stress are 
related to cardiac events in LQTS patients, while positive emotions may be protective 
for the arrhythmia risk (Lane et al., 2009), thus more knowledge of psychological 
issues in affected individuals, is of utmost importance.  
 
Although, general anxiety and depression levels seem to subside over time, disease- 
related anxiety has been reported to remain high over time (Hendriks et al., 2008). 
What factors influence heart-focused anxiety over time needs to be explored. 
 
4.4 Self-efficacy expectations  
Defined by Bandura, self-efficacy is the individual’s capabilities to exercise control 
over events that affects his or her life (Bandura, 1977). Efficacy expectations and 
outcome expectations are important components of self-efficacy. Efficacy expectations 
pertain to a person’s beliefs about his or hers ability to perform the behavior that will 
produce an expected outcome, while outcome expectations pertain to believing in that 
a certain behavior will produce a specific outcome. Self-efficacy is strongly related to 
stress, coping and health and may determine whether specific health behaviors are 
initiated and maintained. The amount of stress and depression in individuals when 
facing a health threat is determined by their own beliefs about their coping abilities 
(Siela & Wieseke, 2000). Self-efficacy can be general or domain specific. In the 
present study self-efficacy is defined as the individual’s beliefs or expectations in 
coping with cognitive, emotional, and behavioral aspects in relation to the genetic 
counseling. A feeling of less personal control have previously been shown to predict 
higher level of distress both before and after genetic testing in persons at risk for 
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different familial cardiac disorders (Long QT syndrome, Hypertrophic 
cardiomyopathy, Dilated cardiomyopathy or Arrhythmogenic right ventricle 
cardiomyopthy)(Hoedemaekers et al., 2007). Therefore, the role of patients’ self-
efficacy expectations should be further explored. 
 
4.5 Satisfaction with genetic counseling 
Patient satisfaction is a significant issue in evaluating medical care (Shiloh et al., 
1990). In the genetic counseling setting it has been emphasized that there is a need to 
assess satisfaction, in order to develop and improve counseling services for the 
patients (Demarco et al., 2004). Typically, patient satisfaction comprises several 
aspects, such as instrumental, affective and procedural satisfaction. The present study 
defines satisfaction with genetic counseling as the patient satisfaction with the 
counselors’ skills of providing medical information (instrumental satisfaction), ability 
to provide psychological support (affective satisfaction), and to satisfaction with the 
situational factors of logistics and practical matters (procedural satisfaction)(Shiloh et 
al., 1990).   
 
Genetic counseling has previously been valued positively among predictively tested 
HCM mutation carriers (Christiaans et al., 2009a), and satisfaction with time spent in 
the clinic, and satisfaction with communication in the clinic has been related to lower 
levels of depression among patients with HCM. However the role of satisfaction with 
genetic counseling in relation to patients’ anxiety is to our knowledge not studied in 
the present patient groups. 
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4.6 State of the art (summary) 
Previous research and clinical experience have identified health- related and 
psychological vulnerabilities in patients with a clinical diagnosis of LQTS or HCM, as 
well as in individuals at genetic risk of LQTS or HCM (Aatre & Day, 2011). However, 
there is still a need for better understanding of the effect of the conditions themselves 
in terms of self-reported health status, as well as a need to explore some of the 
psychological effects (general anxiety and depression) of living with this health threat, 
and further to find out how these patient-reported outcomes are influenced by other 
factors. There is also a need to identify emotional reactions related to living with the 
risk of serious arrhythmias and sudden cardiac death. Heart-focused anxiety may be a 
particular concern for this population. Although several studies have reported cardiac 
symptoms to be strongly related to emotional distress, none have focused on that 
living with fear of cardiac symptoms may increase general anxiety and influence the 
health in individuals who are living with the risk of serious arrhythmias and sudden 
cardiac death. The previous literature has identified factors such as perceived control 
and satisfaction with genetic counseling as important variables in relation to distress 
among these patients. To our knowledge no studies exist on what factors predispose or 
may be important for the prognosis of heart-focused anxiety in individuals with 
familial LQTS or familial HCM who receives genetic investigation and counseling.  
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5. Aims 
5.1 Overall aim 
The overall aim of this study was to obtain more knowledge about the health status, 
levels of general anxiety and depression, and symptoms of heart-focused anxiety in 
individuals living with the risk of serious arrhythmias and sudden cardiac death, 
receiving genetic investigation and counseling because of familial LQTS or familial 
HCM. Figure 5.1 shows investigated variables and proposed relationships.   
5.2 Specific aims 
The aims of the various papers comprising this study are: 
Paper I Baseline 
1. To examine if there is a relationship between living with genetic risk of 
inherited arrhythmia and health status vulnerability.  
2. To explore relationship between socio-demographic variables, clinical status 
and health status domains among the patients coming to genetic counseling. 
 
Paper II Baseline 
3. To investigate these patients’ level of general anxiety, depression and physical 
health and compare the scores to expected scores of the general population. 
4. To investigate the scores of general anxiety, depression, physical health, and 
heart-focused anxiety (avoidance, attention, fear) in patients referred because of 
familial LQTS as compared to the scores of patients referred because of familial 
HCM. 
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5. To assess the role of heart-focused anxiety (avoidance, attention and fear 
symptoms) in relation to general anxiety, depression, and physical health. 
 
Paper III Follow-up 
6. To assess heart-focused anxiety in patients with a clinical diagnosis of LQTS or 
HCM as compared to patients at genetic risk of LQTS or HCM, measured by 
the levels of cardio-protective avoidance, heart-focused attention, and fear 
about heart sensations.  
7. To investigate the independent influence on heart-focused anxiety by the 
following putative predisposing factors; sudden cardiac death in close relatives, 
a recent cardiac death of a relative; patient knowing whether other relatives 
previously have undergone genetic testing; and by factors of possible 
prognostic importance; perceived general health, self-efficacy expectations; and 
satisfaction with genetic counseling (affective, instrumental, procedural 
aspects); while controlling for effects of questionnaire time points, patient 
gender, a clinical diagnosis of LQTS or HCM, and the result of genetic testing.  
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Figure 5.1 Model showing investigated relationships of the patient-reported outcomes, 
socio-demographic variables and clinical variables of patients referred to genetic 
counseling because of familial LQTS or familial HCM, and the comparisons made 
between the scores of the study group, expected scores, or norms of the general 
population. 
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6. Methods 
6.1 Study Designs 
In order to respond to the aims of the study, the following designs were applied in this 
multi-centre study: 
 A cross-sectional design was used to investigate socio-demographic factors 
related to health status domains (Paper I), and to explore if three distinct 
symptoms of heart-focused anxiety (cardio-protective avoidance, heart-focused 
attention and fear about heart sensations) would be related to levels of general 
anxiety, depression, and physical health (Paper II).  
 A comparative design was used to compare SF-36 health status scores of 
patients with familial LQTS or familial HCM (i.e. total sample of patients with 
familial LQTS or familial HCM; patients at genetic risk of LQTS or genetic 
risk of HCM; patients with a diagnosis of LQTS; patients with a diagnosis 
HCM) to that of expected scores of the Norwegian general population, and to 
compare scores according to clinical status (patients at genetic risk of LQTS or 
at genetic risk of HCM; diagnosis of LQTS; diagnosis of HCM) (Paper I), to 
compare general anxiety and depression scores to expected scores of 
Norwegian general population, and physical health to US SF-36 norms, and to 
compare general anxiety, depression, physical health, and heart-focused anxiety 
according to familial disorder (LQTS or HCM)(Paper II), and to compare levels 
of cardio-protective avoidance, heart-focused attention and fear about heart 
sensations in patients at genetic risk of LQTS or genetic risk of HCM as 
compared to patients with a diagnosis of LQTS or diagnosis of HCM (Paper 
III).  
 A prospective design with measurement 2 weeks before genetic counseling, and 
at three time points after the genetic counseling (4 weeks, 6 months and 1 year 
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after counseling) was used to explore relationships between possible predictors 
as measured before, right after genetic counseling and 6 months after genetic 
counseling) and the course and outcome of cardio-protective avoidance, heart- 
focused attention and fear about heart sensations (Paper III).  
6.2 Sample 
The study comprised three samples; a consecutive sample consisting of patients who 
was referred or self-referred for genetic investigation and counseling because of either 
familial LQTS or familial HCM, and two reference populations that were used to 
calculate expected scores of the Norwegian general population. In addition SF-36 US 
norms were used. 
Patients 
The patients were family members and other appropriate relatives subsequently 
following the identification of a LQTS or HCM- causative mutation in an index case 
or individuals in whom a cardiologist had established or suspected a clinical diagnosis 
of LQTS or HCM. Patients were over 17 years of age, not previously genetic tested for 
a familial cardiac disorder, and were consecutively referred or self-referred to genetic 
counseling at the medical genetic departments in Trondheim, Bergen and Oslo. One 
hundred and seventy three patients were consecutively asked to participate in the 
study. A total of 127 patients returned the first questionnaire (one patient was excluded 
from this number in paper II and III because of not answering relevant questions in 
questionnaire), which corresponds to a response rate of 73.4% (T1). Patients dropped 
out during follow-up. Immediately after genetic counseling (T3) 122 patients filled in 
the questionnaire, after four weeks (T4) 85 patients responded, after 6 months (T5) 65 
patients responded, and finally the 1-year follow up (T6) comprised 68 patients. The 
explanation for how the number of patients can increase from one point to the next (as 
from T5 to T6) is that some participants were non-responders at T5, but responded at 
T6. An overview of the number of participants and patient-reported outcome measures 
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at the various assessment times is given in figure 6.1. The characteristics of the 
patients who did and did not complete the one year follow-up questionnaire at T6 did 
not differ significantly for any of the variables.   
 
Reference populations 
The reference populations were based on;  
1) Normative data from the general Norwegian population. SF-36 expected scores 
were calculated based on the data from the Short Form 36 (SF-36) health survey (Loge 
& Kaasa, 1998).  From the 3500 questionnaires sent out, a total of 2323 (67%) 
Norwegian individuals aged 19-80 filled in and returned the questionnaire. Expected 
scores of the general population were calculated based on age and gender of the 
patients.  
 
2) Expected scores of general anxiety and depression were calculated based on 
normative data from the HUNT 2 study (Holmen et al., 2003). A total of 54867 
subjects aged 20 years with complete data on Hospital Anxiety and Depression scale 
(HADS), smoking and education variables, and without self- reported previous 
cardiovascular disease was included in the reference population that formed the basis 
of the regression formula. Expected scores were calculated based on age, gender, 
educational level and smoking habits.  
 
3) US physical health norms according to SF-36 norm-based scoring were used, when 
comparing the physical health scores in the study with a general population (Ware, 
2001). 
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6.3 Procedure 
Ethical approval was obtained from the Regional Committee for Medical Research 
Ethics in Western Norway in September 2004. Data was collected as part of a 
prospective study on the psychosocial implications of diagnosis and counseling in 
hereditary diseases. Information about the study was mailed to the patient together 
with a consent form and the first questionnaire. The participants received one 
reminder. Participants completed measures of health status, general anxiety, 
depression, heart-focused anxiety, self-efficacy expectations, and satisfaction with 
genetic counseling. Questionnaires were collected 2-4 weeks prior to the genetic 
counseling (T1) and 4 weeks (T4), 6 months (T5) and one year after genetic 
counseling (T6). The participants also received a questionnaire immediately prior to 
(T2) and after the genetic counseling session (T3).   
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Figure 6.1 An overview of the patient-reported outcome measures and number of 
participants at various assessment times  
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6.4 The patient-reported outcome measures 
Data on health status domains, general anxiety and depression, heart- focused anxiety, 
self-efficacy expectations, and satisfaction with genetic counseling were obtained from 
patient-reported outcome measures. An explanation of the various patient reported 
outcome measures is provided in table 6.1.  
6.4.1 Short Form-36 Health Survey (SF-36) 
SF-36 is a self-report questionnaire that measures health status (0 = worst health state. 
100 = best health state) on eight sub-scales measuring physical domains (physical 
functioning, role limitation-physical, bodily pain, general health), and mental domains 
(vitality, social functioning, role limitation-emotional, mental health) (Ware & 
Kosinki, 2001). An additional point reports changes in health over the last year. The 
physical domains form the basis to calculate a physical component summary (PCS) 
and the mental domains may be calculated into a mental component summary (MCS). 
The questionnaire is generic and multidimensional and it is suitable for administration 
to large populations and to subgroups such as patients. Its purpose is to be a measure 
of health status or health outcome in cross-sectional and longitudinal studies 
(Hutchinson et al., 1997).  
 
SF-36 was chosen to be the health status measure to be translated in The International 
Quality of Life Assessment (IQOLA) Project, where the goal was to develop and 
validate translations of the health status measure for use in multinational clinical trials 
and other international studies of health (WareJr. & Gandek, 1998). The Norwegian 
translation of the acute version was used in the present study with a 1-week recall 
period (Ware et al., 2001).  
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6.4.2 The Hospital Anxiety and Depression Scale (HADS)  
The HADS measures symptoms of anxiety and depression on two subscales; HADS-
depression (7 items), and HADS-anxiety (7 items) (Zigmond & Snaith, 1983), and has 
been developed not to be influenced by physical symptoms. A higher score means a 
higher level of anxiety or depression (scores ranging from 0-21). It is well suited as a 
screening tool for anxiety and depression, also in patients suffering inherited heart 
diseases, with a cutoff score of 8 to detect cases (Poole & Morgan, 2006). A 
Norwegian translation was available. 
 
6.4.3 The Cardiac Anxiety Questionnaire (CAQ)  
The CAQ consists of 18 items in three subscales pertaining to a) avoidance of 
activities believed to elicit cardiac symptoms (avoidance) b) heart-focused attention 
and monitoring of cardiac activity (attention) and, c) fear and worry about chest and 
heart sensations and functioning (fear) (Eifert et al., 2000a).  Each item is rated on a 5–
point likert scale; indicating how frequently the behavior or symptoms typically 
occurs, ranging from 0 = never to 4 = always. The questionnaire was translated to 
Norwegian by a professional translator with forward and backward translation 
procedure. Subscales, item text, item number and interpretations of the subscales is 
found in paper III, box 1. 
 
6.4.4 The Bergen Genetic Counseling Self-efficacy Scale (BGCSES) 
The BGCSES measures self-efficacy expectations related to genetic counseling. The 
scale comprises of 21 items describing tasks and challenges that are likely to occur 
during and after genetic counseling, and the individual’s beliefs that he or she will be 
able to cope with these. Each item was rated on a scale from 0-10 (0=cannot do at all, 
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10 = can do without difficulty). The average total sum score of the scale was used. The 
BGCSES has been developed using the guidelines of Bandura for constructing Self-
efficacy Scales (revised 2001) Albert Bandura, Stanford University, Palo Alto, CA, 
USA, by a panel of medical geneticists, genetic counselors, and psychologists and has 
been used in related studies (Bjorvatn et al., 2008; Bjorvatn et al., 2009). 
6.4.5 Satisfaction with Genetic Counseling  
The patient’s satisfaction with the genetic counseling was filled in immediately after 
the genetic counseling session. The scale is a 9-item measure which has three 
subscales measuring instrumental, affective and procedural satisfaction (range 3-12) 
(Shiloh et al., 1990). Higher scores indicate greater satisfaction. A Norwegian 
translation was available. 
6.5 Socio-demographic and clinical variables  
The socio-demographic variables were age, gender, marital status, number of 
biological children, employment and education status, and referral by physician/self-
referral through family member. The socio-demographic variables were collected from 
the baseline questionnaire (T1), together with self-constructed questions regarding 
family history of sudden cardiac death, and if the patients knew whether other relatives 
had previously undergone genetic testing (yes, no, uncertain). The rest of the clinical 
variables (having a clinical diagnosis of LQTS, having a clinical diagnosis of HCM, 
and number of patients detected to be mutation carriers) were collected from the 
patients’ medical record. 
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6.6 Statistical methods 
The statistical analyses was performed with SPSS version 15 (Paper I), and 18 (Paper 
II and III) (SPSS Inc., Chicago, IL, USA). Statistical significance was assessed with 
two-sided P < 0.05. Depending on the research questions and the variables different 
types of statistical methodology were used.  
 
Descriptive statistics 
Descriptive analyses have been used in all papers to describe the sample based on 
mean values, standard deviations or standard error of mean, and ranges. SF-36 
expected scores for each of the respondents were calculated for all health status 
domains based on the normative data from the Norwegian population register (Loge & 
Kaasa, 1998), controlling for age and sex (Paper I). Expected values for HADS were 
based on Norwegian reference population data (Holmen et al., 2003), with formula 
controlling for age, sex, educational level and smoking habits (Paper II). Preliminary 
analyses were conducted to assess missing data, normality, and checking for outliers. 
Cronbach’s alpha was computed to determine the internal consistency reliability for 
all questionnaires applied in the study. 
 
Statistical techniques to compare groups 
The unpaired t–test was used to compare mean values,, the chi-square test for 
proportions, and the Mann-Whitney U test for median values between independent 
groups. The paired t-test was used to compare means with repeated measures and to 
compare mean values to expected scores. One-way analysis of variance (ANOVA) with 
post hoc comparisons was used to test differences in the mean scores between three 
groups.  
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Statistical techniques to explore relationships among variables 
Spearman rank correlation was used to explore correlations between the variables.  
Multiple linear regression analyses were used to explore relationship between socio-
demographic, clinical status and health status domains. Hierarchical regression 
analyses were used to assess the role of heart-focused anxiety (avoidance, attention 
and fear symptoms) in relation to general anxiety, depression and physical health, 
beyond relevant covariates. Mixed linear modelling (MLM) was used to investigate the 
independent influence on heart-focused anxiety by the following putative predisposing 
factors; sudden cardiac death in close relatives, a recent cardiac death of a relative; 
patient knowing whether other relatives previously have undergone genetic testing; 
and by factors of possible prognostic importance; perceived general health, self-
efficacy expectations; and satisfaction with genetic counseling (affective, instrumental, 
procedural aspects); while controlling for effects of questionnaire time points, patient 
gender, a clinical diagnosis of LQTS or HCM, and the result of genetic testing.  
 All predictors were entered into MLMs to assess both their main effects and their 
possible interaction with time. 
6.7 Ethical considerations 
The present study has followed the ethical guidelines of the Declaration of Helsinki 
(World Medical Association 1983. Approval from the Regional Committee for 
Medical Research Ethics, Western Norway was obtained 01.09.04 (REK VEST # 
128.04). In addition, the study was approved by the Norwegian Social Science Data 
Services (# 11289).  
 
Three primary ethical principles for protecting study participants are beneficence, 
respect for human dignity, and justice (Polit & Beck, 2008). To protect the study 
participants’ rights, procedures were followed to ensure that the individuals were 
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guaranteed anonymity and the right to withdraw from the study at any time. The 
participants were provided with a letter with information needed to make a reasoned 
decision about participation in the study, and additionally a consent form had to be 
actively returned together with the first questionnaire. In a risk/benefit assessment it 
was concluded that there was no high risk that participation in the study should lead to 
any physical or psychological harm. However, the study provided possibility to refer 
patients to a psychologist specialist if that was deemed necessary.  The study 
conformed to that patients have the right to fair treatment, and in accordance with the 
biotechnology act that states that patients undergoing predictive genetic testing should 
be provided with genetic counseling (Act of biotechnology in human medicine, 2003, 
appendix), all patients were given the same intervention if they participated in the 
study or not.  
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7. Results 
A summary of the individual papers I-III with main results are presented in the 
following chapters. 
7.1 Sample characteristics 
Socio-demographic and clinical variables of the sample are shown in Table 7.1. The 
mean age was 45 years (range: 17-83), most were married or cohabitating (77.2 %), 
had children (78.0 %), and were employed (67.7 %). Few had a clinical diagnosis of 
LQTS (9.4%) or HCM (15.7 %). Approximately half of the sample (44.9 %) reported 
that there had been a sudden cardiac death in a relative. More than half of the patients 
(60.6%) knew that other relatives previously had undergone genetic testing. One 
hundred and thirteen patients (89.0 %) were offered and consented to genetic testing. 
The result of genetic testing in the current sample showed that a mutation was detected 
in 44 individuals (34.6 %). Descriptive information of the patient-reported outcomes 
are presented in table 7.2. 
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Table 7.2 Descriptive information of the patient- reported outcomes 
Questionnaires Time 
point 
N Mean SD SEM Min/max Cron-
bach’s 
alpha
Short Form 36 (SF-36)   
Physical functioning T1 122 88.18 16.35 1.48 28.57-100.00 0.87
Role physical T1 126 78.24 35.54 3.17 0.00-100.00 0.89
Bodily pain T1 127 78.34 25.91 2.30 0.00-100.00 0.92
General health T1 126 69.54 20.54 1.83 0.00-97.00 0.71
Vitality  T1 127 55.73 24.80 2.20 0.00-100.00 0.91
Social functioning T1 127 83.37 22.88 2.03 0.00-100.00 0.88
Role emotional T1 124 77.82 36.85 3.31 0.00-100.00 0.87
Mental health T1 127 76.30 19.47 1.73 4.00-100.00 0.90
PCS T1 120 50.55 8.61 0.79 24.87-64.28 0.88
MCS T1 120 48.93 11.63 1.06 6.41-63.44 0.94
Hospital Anxiety and 
Depression Scale 
(HADS)  
  
General anxiety T1 125 4.90 4.00 0.36 0.00-18.00 0.83
Depression T1 125 3.11 3.72 0.33 0.00-17.00 0.87
The Cardiac Anxiety 
Questionaire (CAQ) 
  
Avoidance T1 125 0.93 0.82 0.07 0.00-3.30 0.88
 T4 79 0.88 0.88 0.10 0.00-3.20 0.92
 T5 64 1.01 0.95 0.12 0.00-3.20 0.91
 T6 67 0.96 0.89 0.11 0.00-2.98 0.92
Attention T1 126 0.76 0.68 0.06 0.00-2.80 0.79
 T4 79 0.75 0.71 0.08 0.00-3.40 0.66
 T5 64 0.72 0.60 0.08 0.00-2.80 0.80
 T6 67 0.73 0.67 0.08 0.00-2.80 0.82
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Fear T1 125 1.19 0.79 0.07 0.00-3.50 0.84
 T4 79 1.21 0.74 0.08 0.25-3.88 0.86
 T5 64 1.23 0.74 0.09 0.00-3.63 0.84
 T6 67 1.18 0.78 0.10 0.00-3.75 0.87
Self-efficacy 
expectations (BGCSES) 
T1 121 8.27 1.90 0.17 0.44-10.00 0.96
Satisfaction with 
Genetic Counseling 
(SCS) 
  
Instrumental (range:3-12) T1 113 10.61 1.51 0.14 5.00-12.00 0.67
Affective(range:3-12) T1 112 11.58 1.04 0.10 5.00-12.00 0.81
Procedural (range:3-12) T1 108 11.00 1.37 0.13 6.00-12.00 0.62
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7.2 Health status in patients at risk of inherited arrhythmias 
and sudden unexpected death compared to the general 
population (Paper I) 
 
When investigating health status domains, the results indicated that the total sample 
(N =127) differed from the general population scores by perceiving their general 
health to be poorer (controlled for age and gender). When comparing the individual 
subgroups (genetic risk of LQTS or HCM, diagnosis of LQTS, diagnosis of HCM) to 
expected general population scores, the patients at genetic risk and patients with a 
clinical diagnosis of HCM had lower general health scores. In addition the latter 
group had poorer perceived health related to physical functioning, role physical, 
vitality and role emotional domains. Comparing the subgroups to each other further 
supported that patients with a clinical diagnosis of HCM were the most vulnerable 
group in physical health domains. In general, employment, higher education and 
being referred to genetic counseling through a family member were associated with 
better scores on the health status domains.  
7.3 General anxiety, depression and physical health in 
relation to symptoms of heart-focused anxiety- a cross 
sectional study among patients living with the risk of 
serious arrhythmias and sudden cardiac death (Paper II) 
 
Assessing general anxiety and depression showed that 24.6 % of the patients had 
scores above cut-off for anxiety and 13.5 % for depression. Overall the patients 
included in the study (n = 126) reported significantly higher levels of general anxiety 
compared to expected scores of the general population, but there were no significant 
differences in depression levels. There were also no significant differences between 
having a diagnosis of LQTS or HCM, and being at genetic risk of LQTS or HCM, 
59 
 
with regards to levels of general anxiety and depression. Moreover, physical health 
did not differ significantly from expected scores. However, the subgroup of patients 
with clinical diagnosis of LQTS or HCM (n = 31) showed poorer physical health as 
compared to expected scores, whereas patients at genetic risk (n = 89) scored better 
on physical health as compared to expected scores. 
 
When comparing the patients with familial LQTS to patients with familial HCM, 
there were no significant differences with regard to the level of general anxiety and 
depression, whereas poorer physical health and higher scores of heart-focused anxiety 
(avoidance, attention, fear) were found in the latter group.  
 
When investigating the role of heart-focused anxiety (cardio-protective avoidance, 
heart-focused attention and fear about heart sensations), the following was found; 
higher avoidance and fear scores were independently related to higher scores of 
general anxiety, depression, and lower scores of physical health beyond relevant 
covariates (age, gender, having children, diagnosis of LQTS or HCM, and recent 
cardiac death in the family). A recent cardiac death in the family made a significant 
contribution to the final models predicting higher levels of general anxiety and 
depression.   
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7.4 Predictors of heart-focused anxiety in patients 
undergoing genetic investigation and counseling of Long 
QT syndrome or Hypertrophic cardiomyopathy: A one year 
follow-up (Paper III) 
 
Investigating heart-focused anxiety over a time period of up to one year showed that 
scores for avoidance, attention and fear were overall higher in patients with a clinical 
diagnosis of LQTS or HCM as compared to patients at genetic risk. With exception, 
at four weeks after genetic counseling (T4) avoidance and fear scores were not 
significantly different across groups and at six months after genetic counseling (T5) 
there was no significant difference in attention scores. 
 
Results from mixed linear modelling showed that predisposing factors of heart-
focused anxiety were a close relative’s sudden cardiac death (predicting higher 
attention and fear levels), uncertainty whether other relatives previously had 
undergone genetic testing (predicting higher levels of attention). Factors of 
prognostic importance for heart-focused anxiety were poorer perceived general health 
(predicting higher avoidance, attention, and fear levels), higher levels of self-efficacy 
expectations (predicting lower fear levels) and procedural satisfaction with genetic 
counseling (predicting lower levels of avoidance and attention). In addition female 
gender predicted higher levels of fear and receiving a mutation positive test result 
predicted a higher avoidance level at 6 months after genetic counseling (T5).   
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8. Discussion 
8.1 Summary of findings 
The overall aim of this study was to obtain more knowledge about the health status, 
levels of general anxiety and depression, and symptoms of heart-focused anxiety in 
individuals receiving genetic investigation and counseling because of familial LQTS 
or HCM. This study is the first in Norway investigating, by means of validated and 
standardized patient-reported outcome measures, the health status, levels of general 
anxiety and depression levels in the patients receiving genetic counseling for LQTS 
or HCM. To the best of our knowledge it is also the very first to investigate the role 
of heart-focused anxiety in relation to general anxiety, depression  and physical 
health, and exploring prospectively predictors of heart-focused anxiety among these 
individuals who are living with the risk of serious arrhythmias and sudden cardiac 
death.  
 
Compared to expected scores of the general population the total group of patients had 
poorer general health and higher levels of general anxiety. Patients with a clinical 
diagnosis of HCM were especially vulnerable in both physical and mental health 
domains.  There were no significant differences between groups (patients at genetic 
risk vs. patients with diagnosis; familial LQTS vs. familial HCM) in terms of levels 
of general anxiety and depression. Especially two distinct symptoms of heart-focused 
anxiety were related to general anxiety, depression and physical health, namely 
avoidance and fear. By assessing heart-focused anxiety in patients with a clinical 
diagnosis as compared to patients at genetic risk, it was found that patients with a 
clinical diagnosis overall had significantly higher scores of avoidance, attention and 
fear. However, predisposing factors for heart-focused anxiety over time were a close 
62 
 
relative’s sudden cardiac death and uncertainty whether other relatives previously had 
undergone genetic testing. Other variables of prognostic significance for heart-
focused anxiety over time were perceived general health, self-efficacy expectations 
and procedural satisfaction with genetic counseling.  
 
The following sections will consider some methodological issues and discuss the 
main findings of the study. 
8.2 Methodological issues 
 
The present study has several strengths such as the one-year follow up time, the 
inclusion of consecutive patients at three University hospitals in Norway within a 
specified time period, and the use of standardized and validated patient-reported 
outcome measures. However, there are also some weaknesses that need to be 
addressed pertaining to the study designs, sample and patient-reported outcomes. The 
strength and weaknesses will be discussed further in the following sections.  
8.2.1 Study Designs 
In order to reach the specific aims of the study several non-experimental designs were 
implemented; a cross-sectional design, a comparative design, and a prospective 
design.  
 
The cross-sectional design 
A cross-sectional design was included as the first step in the present prospective 
study, thus the socio-demographic, clinical variables, and patient-reported outcomes 
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were defined at baseline. Strengths of cross-sectional designs pertain to that they are 
fast, inexpensive and there is no loss to follow-up (Hulley et al., 2007). For 
descriptive purposes a cross-sectional design is adequate and the design can reveal 
cross-sectional associations, however a limitation of the design was that it gave only a 
snap-shot picture of the patient’s health status, general anxiety, and depression levels 
as they were 2-4 weeks before the genetic counseling session (paper I and II). 
Limitations in drawing conclusions about causality and direction of relationships 
between the independent and dependent variables therefore exist.  
 
The comparative design  
The comparison of health status, general anxiety, and depression scores in the sample 
with expected scores of the general population was a clear strength of the study, since 
assessing symptoms based on cut-off points may have little clinical significance, 
when a context for understanding the findings is not provided (Polit & Beck, 2008). 
Confounding variables may be a weakness in a comparative design. The comparison 
between health status in the samples and expected scores of the general population 
were controlled for age and gender, and the comparison of general anxiety and 
depression to expected scores of the general population were controlled for age, 
gender, education level, and smoking habits. These variables were therefore 
eliminated as confounding variables. In comparing the different groups the influences 
of confounding variables were not controlled for, thus these results must be 
interpreted with extra caution.  
 
The prospective design  
We were fortunate to have the possibility to follow-up patients up to one year after 
genetic counseling. Prospective designs are used for assessing incidence, and are well 
suited for investigating potential causes for a condition or an outcome (Hulley et al., 
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2007). Thus, it was well suited for investigating predictors of heart-focused anxiety. 
There are several strengths of using a prospective design. First of all it establishes the 
time sequence of the variables. Second it prevents predictors from being influenced 
by the outcome itself, and finally measuring variables prospectively will give a more 
accurate and complete result, as compared to measuring variables retrospectively. 
This was especially important in the present study, as predictors such as perceived 
general health, self-efficacy expectations, and satisfaction may be difficult for the 
patient to remember after some time. The general weaknesses of the design pertain to 
the challenges of making causal inferences and controlling confounding variables 
(Polit & Beck, 2008). In addition the design is time-consuming, costly, and 
inefficient in studying rare outcomes. However, the design may be appropriate 
studying an outcome such as heart-focused anxiety among patients that are living 
with the risk of serious arrhythmias and sudden cardiac death, as compared to 
studying heart-focused anxiety in for example a normal population.  
 
8.2.2 Sample 
Choosing the study subjects 
To ensure that the findings in a study accurately represent the population in interest, 
the selection of study subjects is very important (Hulley et al., 2007). At the time 
when this study was initiated clinical genetic investigation of familial cardiac 
disorders had just started in Norway. To obtain more knowledge about the patients, 
the aim of the study was to investigate the health status, levels of general anxiety and 
depression, and symptoms of heart-focused anxiety in individuals that were 
undergoing genetic investigation and counseling for LQTS or HCM. The patients 
were family members and other appropriate relatives subsequently following the 
identification of a LQTS or HCM- causative mutation in an index case or individuals 
in whom a cardiologist had established or suspected a clinical diagnosis of LQTS or 
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HCM. This heterogeneous study sample was chosen based on expectations that the 
entities by themselves would not produce big enough sample sizes, thus a pragmatic 
approach was needed. A pragmatic approach could be justified partly because, the 
two entities, LQTS and HCM share a lot of common features, especially with regard 
to the risk of arrhythmia, syncope, and sudden cardiac death, and how they are 
managed in the genetic counseling setting, and partly because both patients with a 
clinical diagnosis as well as their relatives at genetic risk may manifest serious 
symptoms.  We therefore investigated a sample of patients fulfilling the inclusion 
criteria in their natural contact with the genetic outpatient clinic. Every accessible 
person who met the entry criteria in three different regional tertiary hospitals was 
consecutively included to minimize volunteerism and other selection biases (Hulley 
et al., 2007).  
 
Number of study subjects 
A priori computations had been made regarding a needed sample size of 250 for 
detecting small and moderate changes, and for comparisons within the group and 
between groups based on two-tailed tests, alpha-level of 0.05, and power of 0.80. 
However, despite that several steps were taken to increase the response rate, such as 
pre-stamped, pre-addressed return envelopes, and one repeated contact attempt by 
post asking non-responding patients to participate in the study, it was not possible to 
reach this sample-size, partly due to the non-responders, but also that there were not 
enough eligible participants within the time frame of the study. The limited number 
of patients attending genetic counseling for familial LQTS or familial HCM made it 
especially difficult to achieve sufficient sample sizes according to the previous power 
estimates of the study. This may also explain some of the unexpected insignificant 
results in the smaller subgroups. 
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Non-response and loss to follow-up 
In achieving a representative sample a particular concern is non –response. The level 
of non-response may compromise the generalizability of the study (Hulley et al., 
2007). Of 173 eligible patients, one hundred and twenty-seven patients were willing 
to participate (73.4 %), which may be considered a satisfactory response rate. 
However a non-response rate of 26.6% at baseline may influence the results. We do 
not have any information about this group as we were not allowed to register 
information on the decliners. For example, in case of an under-representation of 
individuals with a “severe family history” this may result in weaker observed effects 
on, for example, psychological variables. 
 
Furthermore, on the course of the study patients dropped out, which may cause 
attrition bias (Polit & Beck, 2008). The explanation for how the n can increase from 
one point to the next (as from T5 to T6) is that some participants were non-
responders at T5, but responded at T6. At one year after genetic counseling, 58 
individuals had dropped out. However, there were no significant differences between 
the study sample and these drop-outs on any of the variables in the prospective study 
(paper III, table 1). The fact that not all participants completed all time points could 
potentially also cause problems for the statistical analysis. In order to meet this 
weakness the method of Mixed Linear Method was used. It is designed for tracking 
changes over time, even with missing data at certain questionnaire time points. The 
method uses all available data and can account for correlations between repeated 
measurements on the same subjects and has flexibility to model time effects. 
 
Patients’ subcategories 
At the time when the study started the patients attending genetic counseling for 
familial cardiac disorders mainly consisted of LQTS or HCM patients and their at- 
risk relatives. We therefore included patients with a clinical diagnosis as well as 
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unaffected patients with a presumed genetic risk. However, these subcategories may 
be regarded as very different. We could not fully address these differences in the 
present study, thus this could introduce bias, although we did subgroup analyses in all 
of the papers. By considering patients at family risk, patients with a clinical diagnosis 
of LQTS, and patients with a clinical diagnosis of HCM separately in the comparison 
to expected scores of the general population, it was ensured that patients similar 
according to clinical status were compared to the expected scores. It was however a 
limitation that the groups were so different in size, when comparing them to each 
other.  
 
More patients with familial LQTS were included in the study as compared to patients 
with familial HCM, despite that HCM is a more prevalent disease. The reason for this 
may be that the possibility of genetic testing for LQTS started in 2001, whereas 
molecular genetics for HCM was only possible from 2004, thus the possibilities of 
genetic investigation may therefore not have been widely known among HCM 
patients and their physicians in the study period. LQTS molecular testing may also be 
perceived as more important for diagnostics, since patients with normal ECGs and no 
clinical manifestations still may be at risk.  
8.2.3 The patient-reported outcomes 
The patient-reported outcome measures were selected based on the aims of the 
present study, previous research, clinical experience, and the patient-reported 
outcome literature. Main strengths of the study were the use of well-established, 
standardized, validated questionnaires. An exception is the The Bergen Genetic 
Counseling Self-efficacy Scale (BGCSES), which has not been validated, but has 
been constructed based on Banduras guidelines (see section 6.4.4). The instrument 
has shown high reliability in previous studies (Bjorvatn et al., 2008; Bjorvatn et al., 
2009). A generic questionnaire measuring patient general health and wellbeing, as 
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well as questionnaires that measured specific dimensions to a greater extent were 
selected as patient-reported outcomes. The advantage of using generic instruments is 
that they can be used in general population trials or across patients with different 
disease conditions (Fayers & Machin, 2007). For example, SF-36 is not age, disease 
or treatment specific, and has therefore several advantages. It is applicable to patients 
with more than one disease, and it can be used to compare patient-groups who suffer 
from different diseases (Loge et al., 1998). It is therefore appropriate in the present 
study where the sample consists of patients presumed to be at genetic risk of LQTS or 
HCM, as well as patients who already have a diagnosis of LQTS or HCM due to 
clinical findings, and of two reference populations from which expected scores of the 
general population were calculated.  
 
The advantages of using a dimension-specific instrument pertain to documenting 
dimensions that are of special interest or particularly important to the patient group in 
question (Fayers & Machin, 2007). For example, it is likely that anxiety among 
patients with a suspected risk of heart conditions will be related at some level to the 
functioning and sensations of the heart. A dimension-specific instrument like CAQ 
would capture this, whereas a generic questionnaire would be inadequate. A negative 
consequence of including both generic and dimension-specific instruments in the 
present study was that the questionnaire package took a long time to complete for the 
patients. This may have led to missing items on some of the questions. Missing 
substitution was performed according to standard procedures for the SF-36 
questionnaire (Medical Outcomes Trust, 1994). For the remaining questionnaires 
mean imputation were used, where over half of the questions were filled in (Fayers & 
Sprangers, 2002).  
 
The questionnaires have shown good reliability in previous studies. In the present 
study, Cronbach’s alpha (Table 7.2) was in general good, with exception of the 
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subscale of procedural satisfaction. This may be due to the few items of this scale 
(Fayers & Machin, 2007).  
 
In the following sections, central findings regarding the patient-reported outcomes, 
impact of socio-demographic and clinical variables, the influence of having a family 
history of sudden cardiac death, and the role of heart-focused anxiety in relation to 
patient-reported outcomes will be discussed. Furthermore, this discussion will 
explore possible explanations for differences in patient-reported heart-focused 
anxiety up to one year after genetic counseling, and discuss some emerging issues 
relating to the contents and optimal dimensions of health care services in the future. 
8.3 Patient- reported health status, levels of general 
anxiety and depression, and symptoms of heart-focused 
anxiety  
 
Health status 
The present study demonstrates reduced health status in the SF-36 domain of general 
health in individuals receiving genetic investigation and counseling because of 
familial long QT syndrome (LQTS) or familial hypertrophic cardiomyopathy (HCM). 
Approximately 75 % of these individuals were termed “patients at genetic risk” 
because they were family members and other appropriate relatives subsequently 
following the identification of a LQTS or HCM- causative mutation in an index case, 
and thus without a clinical diagnosis. In line with that the patients at genetic risk 
currently were clinically unaffected by LQTS or HCM, these patients had better 
health status scores on physical functioning and the bodily pain domains compared to 
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the expected scores of general population. However, by their own the patients at 
genetic risk also had markedly reduced general health scores.  
 
In our study general health is defined as current health, resistance to illness, and 
health outlook, which can be considered to belong to one overall dimension of 
perceived health (Bjorner & Kristensen, 1999). Perceived health allows the patients 
to weigh together different aspects of their health in an overall score, thus the aspects 
that the patient deem relevant is emphasized (Fayers & Sprangers, 2002).  Living 
with the risk of serious arrhythmias and sudden cardiac death implies a probability 
for something adverse can happen in the future. LQTS and HCM are autosomal 
dominant disorders, which mean children, siblings and parents of a mutation carrier 
have a 50 percent risk of also being affected, thus they are also living with risk of 
serious cardiac symptoms. The penetrance (likelihood for actually developing the 
disease) is however varying, which leads to uncertainty of ever experiencing clinical 
symptoms of the disorder. Living with this health threat may cause the patients to feel 
vulnerable. In turn, this perceived vulnerability may result in poorer perceived 
general health. 
 
In contrast to the poorer perceived general health, physical functioning, role 
limitation-physical, bodily pain, vitality, social functioning, role limitation-emotional, 
and mental health domains were not significantly different as compared to expected 
scores in the general population. However, all health status domains were influenced 
by clinical variables as well as socio-demographic variables. 
  
With regard to the adult population affected with LQTS or HCM, health status has 
previously only been measured with well-established, standardized and validated 
measures in HCM patients, indicating that patients with a clinical diagnosis of HCM 
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have major limitations on both physical and mental health domains (Cox et al., 1997). 
Although many patients with HCM can be asymptomatic, clinical manifestations 
such as dyspnea, dizziness, syncope and angina are common (Stroumpoulis et al., 
2010). The presence and severity of symptoms may most likely be the reason for 
reduced scores in physical and role physical activities as well as the lower scores on 
the vitality domain. The HCM patients in the present study were not significantly 
different from the general population on levels of bodily pain, social functioning, or 
mental health. However they did have poorer perceived general health. 
 
In contrast to the limitations the HCM patients experienced, the scores of the LQTS 
patients were not significantly different than those of the general population on any of 
the health status domains. However, the group may have been too small to detect 
significant differences, and it is worth to note that the scores on several of the health 
status domains were moderately lower also among the LQTS patients. This was 
especially pertaining to general health and vitality, where the differences in scores 
may be an indication of poorer perceived health. Being a generic instrument, 
measuring patients general health and wellbeing, the SF-36 may not completely 
capture the health problems of LQTS patients, since qualitative research clearly have 
found evidence of daily limitations related to periodic feelings of extreme fatigue, 
exhaustion, palpitations and headaches in this patient group (Andersen et al., 2008).   
 
Variables like gender, age and education status were expected to have an influence on 
health status since they are common confounders in health research using patient-
reported outcome measures (Polit & Beck, 2008). Health status was therefore 
investigated in relation to socio-demographic variables. As to gender differences 
previous research has shown gender differences in anxiety disorders and symptoms 
(Lewinsohn et al., 1998). We found that female gender was related to lower scores on 
domains that measure well-being, such as bodily pain, vitality, and mental health. 
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Patients that had children also scored lower on mental health. This is understandable, 
since much of the literature has identified raised anxiety levels in parents having 
children at risk of these disorders (Hendriks et al., 2005b; Hendriks et al., 2005a). 
Increasing age had an impact on physical health. Lower education level indicated 
poorer health status, as can also be found in general population samples (Loge & 
Kaasa, 1998). Physician referral to genetic counseling was related to poorer health 
status on all health domains. Referral from a physician may therefore indicate that the 
patient more likely was clinically affected.  
 
General anxiety and depression 
While there were large differences in health status according to clinical status, no 
differences were found in terms of general anxiety and depression between patients at 
genetic risk and patients with a clinical diagnosis. The anxiety levels were elevated 
compared to the general population controlled for gender, age, education level, and 
smoking status. The prevalence of general anxiety (scores over >8, HADS) in the 
patients before genetic counseling was 25%, which is quite high in comparison to the 
prevalence among Dutch HCM mutation carriers (Christiaans et al., 2009b), and the 
prevalence in general population samples (13-18%). It was however comparable to 
the proportion of patients anxious before attending genetic counseling for hereditary 
cancer (Bjorvatn et al., 2008). Receiving the invitation to participate in the study and 
the scheduled genetic counseling session may have actualized anxiety in some of the 
individuals. However, it cannot be ruled out that living with this health threat in itself 
may have an impact on levels of general anxiety.  
 
Heart-focused anxiety 
In contrast to that there were no differences in general anxiety between any of the 
groups, patients with a clinical diagnosis had significant higher levels of heart-
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focused anxiety than the patients at genetic risk, and patients receiving genetic 
counseling because of familial HCM had higher levels of heart-focused anxiety 
compared to patients receiving genetic counseling because of familial LQTS. In terms 
of explaining possible reasons for a relationship between greater heart defect 
complexity and higher levels of heart-focused anxiety, Ong and colleagues suggested 
that patients with greater defect complexity may be more symptomatic, have greater 
functional impairments, and have a history of more medical interventions that may 
trigger heart-focused anxiety (2011). This may also be the case for patients with 
clinical diagnoses, and especially the HCM patients. Therefore, higher heart-focused 
anxiety among patients affected clinically, especially with HCM may most likely be 
due to that they experience more symptoms, functional impairments, and contact with 
health care services that can trigger fear for adverse outcomes. 
 
In summary, patients with a clinical diagnosis had poorer physical health and higher 
levels of heart-focused anxiety, whereas patients at genetic risk scored better on these 
domains. Common for the patients at genetic risk of LQTS or HCM and patients with 
a diagnosis of LQTS or HCM, were poorer perceived general health and higher levels 
of general anxiety.   
 
8.3.1 The impact of having a family history of sudden cardiac 
death  
One consequence of living in a family with a familial cardiac disorder is the 
possibility that a relative suffers a cardiac arrest and dies unexpectedly. Fifty–seven 
individuals (45%) had experienced sudden cardiac death in a relative. Thirty-five of 
these individuals (28%) had experienced sudden cardiac death in a close relative (first 
or second degree relative), and 25 individuals (20%) had experienced that a relative 
had died of a cardiac arrest less than a year ago.  
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In the present study it was found that having a family history of sudden cardiac death 
impacted on several of the patient- reported outcomes. Counter intuitively, when 
investigating socio- demographic variables relationship to health status domains, it 
was found that patients that had reported a sudden cardiac death event among any of 
their relatives at any point in time, had higher scores on the health domain of bodily 
pain (less bodily pain). This result may have been confounded, but it may also be 
evidence of a response shift. Experiencing a relative’s death event may be very 
dramatic, and it is possible that an event like that can change a person’s self-
evaluation as to having less bodily pain or no bodily pain, as opposed to more 
(Schwartz et al., 2007). The better physical health scores than expected among the 
patients at genetic risk in the present study may also be due to similar mechanisms.  
 
Psychological processes may be involved, since we found that the experience of a 
recent cardiac death of a relative was associated with higher levels of general anxiety 
and depression. Patients may also not relate a sudden cardiac death event in the 
family so negatively to general bodily pain as they would to specific perceived heart 
symptoms, which more likely will represent a greater extent health threat. The latter 
alternative was supported by the fact that a sudden cardiac death event in a close 
relative (first or second degree relative) predicted higher levels of heart-focused 
attention and fear about heart sensations up to one year after genetic counseling.  
8.3.2 The role of heart-focused anxiety 
The fear of cardiac-related events and sensations may potentially also in itself 
contribute to higher levels of general anxiety and influence heart-related illness 
(Eifert et al., 2000b). For example, in a study of patients undergoing cardiac surgery, 
Hoyer et al.,(2008) found that heart-focused anxiety was significantly correlated with 
higher levels of anxiety and depression and lower health –related quality of life, and 
Zvolensky et al., (2003) found that heart-focused attention and fear about heart 
sensations predicted self-reported chest pain intensity among patients with coronary 
75 
 
disease. In the present study two distinct symptoms of heart-focused anxiety, the 
degree of cardio-protective avoidance and fear about heart sensations, could explain a 
considerate part of the higher levels of general anxiety and depression in the patients, 
in addition to patients lower scores on physical health. First, cardio-protective 
avoidance is a recommendation to avoid aversive events in patients with the risk of 
serious arrhythmias. Knowing that activity actually can trigger events may therefore 
in itself cause patients to avoid all kinds of activity and fear any heart sensation, 
which would impact on physical health as well as on general anxiety and depression. 
Secondly, both avoidance and fear may be due to that the patients actually have 
poorer health. It is therefore difficult to interpret whether avoidance and fears in 
relationship to physical health is due to medical recommendations for patients that are 
affected, or that the avoidance and fear is due to poorer health. However, high levels 
of avoidance and fear may be considered as important risk factors for higher levels of 
general anxiety and depression, as well as poorer health functioning.  
8.3.3 Explanations for differences in heart-focused anxiety up to 
one year after genetic counseling 
Research on patients undergoing genetic counseling has so far mostly focused on the 
possible negative effects of genetic testing. Complementary to this, the present 
findings show that knowing whether other relatives had undergone genetic testing, 
higher self-efficacy expectations, and higher levels of procedural satisfaction after 
counseling actually reduced fearful responses to cardiac-related stimuli and 
sensations over time. This indicates less heart-focused anxiety among patients that 
knew there would be possibilities of genetic testing, that thought they would cope 
with challenges connected to the genetic counseling, and that were more satisfied 
with waiting time and administrative tasks around the counseling session.  
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In addition the present findings underline the importance of the patients’ perspective 
of health. Interestingly, poorer perceived general health as measured before genetic 
counseling was an important predictor for heart-focused anxiety, as it predicted 
avoidance, attention, as well as fears up to one year after genetic counseling. 
Perceived general health has previously been shown to influence clinical outcome, as 
well as being a powerful predictor of mortality and morbidity (Fayers & Sprangers, 
2002). In a study reporting predictors of 10-year survival in women after acute 
myocardial infarction, those that perceived poorer general health had a two times 
higher risk of dying (Norekval et al., 2010), thus it may be a variable of particular 
interest to study in future studies in the present patient group, since they have poorer 
perceived general health as compared to the general population.  
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8.4 Emerging issues related to genetic investigation and 
counseling now and in the future 
 
The rapidly developing gene technology has made it possible to identify individuals 
with an increased risk for diseases. This development will likely have substantially 
impact on future treatment and care.  With an increasing number of individuals 
seeking genetic investigation for familial cardiac disorders, finding ways to maintain 
a high health functioning and emotional wellbeing among the patients are essential to 
be able to argue for increased use of genetic testing in cardio-genetic care.  
 
Today diagnostic genetic testing in Norway can be performed without prior genetic 
counseling, whereas patients undergoing predictive genetic testing are protected by 
the law and are entitled to genetic counseling before, during, and after the testing 
(Act of biotechnology, 2003, appendix). Patients clinically affected by disease should 
also be entitled to genetic counseling before genetic investigation, because finding a 
mutation has further consequences than just confirming the diagnosis in that 
individual. For example, higher levels of heart-focused anxiety were found in the 
patients with a diagnosis compared to patients at genetic risk. The genetic counseling 
provides a venue for addressing heart-focused anxiety. Further, current practice of 
genetic counseling includes information and performance of cascade genetic testing 
of at-risk relatives. As discussed in Hamang et al., (2009) the current Act of 
Biotechnology does not automatically allow communication of genetic information to 
persons other than the patient. This means that the patients themselves have to be 
instrumental in informing other relatives of genetic test results and risks. Index 
patients with clinical diagnosis may therefore have even greater need for genetic 
counseling, because they have to inform others.  
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Common for LQTS and HCM patient groups, before genetic investigation and 
counseling, were a higher general anxiety level compared to what is expected in the 
general population beyond reported health status or whether the patients were 
affected or unaffected with the familial disorder. The higher general anxiety level 
may have been due to the upcoming genetic counseling session. However a more 
likely explanation may be that general anxiety is an important determinant for 
undergoing genetic testing in the first place, since previous research has shown 
decreased levels of general anxiety over time in for example patients undergoing 
predictive genetic testing for familial LQTS  (Hendriks et al., 2008). In the present 
study it was shown that the patients had high satisfaction with genetic counseling, 
and that satisfaction with the procedural parts of genetic counseling decreased heart-
focused anxiety levels. The continuation of genetic counseling is therefore necessary 
in the future.  
 
Following the protocol of predictive genetic testing, most of the patients that were 
offered genetic testing, underwent testing. This is clearly different from our 
experience in cancer counseling, where more patients decline genetic investigation 
after counseling. There may be several explanations for this. It may for example be 
due to that the protocol of predictive testing of patients is different in cardiac 
disorders compared to cancer, since the decision to undergo testing is not postponed, 
because of the immediate risk of symptoms and sudden death, the greater risk in 
young age, and that preventive measures are available. Alternatively, it may also be 
due to that there are greater detection rates in the genetic testing of cardiac disorders, 
and that the result of the testing has more consequences in terms of preventive 
measures. Even though there are positive aspects of finding a mutation, like 
surveillance and other medical strategies to reduce risk of sudden cardiac death, the 
patients often have to wait a long time for a heart control. A more team-based 
approach between the genetic counselor and cardiologist may be beneficial for the 
patient to cope with a positive genetic test result. 
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The field of medicine has become highly specialized. The application of genetics to 
cardiology is one example where the care of patients involves medical, psychological, 
and familial challenges, of which the present health care system may lack expertise 
and resources to oversee (Patterson, 2009). The purpose of a more team based 
approach must be to offer the patients and their families an optimal cardiological and 
genetic examination and follow-up as well as increasing knowledge among patients, 
their families, and the health care personnel.  
 
The clinical guidelines emphasize the importance of genetic testing in LQTS families 
and the usefulness in families with HCM (Zipes et al., 2006) in the prevention of 
serious arrhythmias and sudden cardiac death. The clinical guidelines should also 
include the importance of genetic counseling as stated in the recent expert consensus 
recommendations of genetic testing for the channelopathies and cardiomyopathies 
(Ackerman et al., 2011).  
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9. Conclusions 
The studies included in this thesis show that the use of patient-reported outcome 
measures allows for better understanding, not only of the effect of the conditions 
themselves, but also of some of the effects of living with this health threat, and finally 
of how outcome is influenced over the course of the study. The three papers included 
in the present thesis elaborate on these findings. The following conclusions were 
made: 
 
Paper I: 
In a cross-sectional design it was found that living with the risk of serious 
arrhythmias and sudden cardiac death most likely affects the perceived general health 
in patients receiving genetic counseling for familial LQTS or familial HCM. 
However the patients’ scores on the other health status domains were not impaired 
compared to what is expected in the general population.  
 
There were however significant differences of the effect of the conditions themselves. 
Patients with a clinical diagnosis of HCM reported more impairment compared to the 
general population in physical functioning, role physical, and vitality domains, 
whereas patients with family risk of LQTS or HCM reported better physical 
functioning and less bodily pain. 
 
Several socio-demographic variables and clinical variables were related to better 
perceived health status, notably employment, higher education level and referral to 
genetic counseling by a family member. Better self-reported physical functioning and 
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general health were in addition predicted by that the patients were referred for 
familial LQTS as opposed to familial HCM, supporting that the HCM patients were 
the most vulnerable in physical health domains.  
Paper II: 
 
Before receiving genetic counseling, the individuals with familial LQTS and familial 
HCM had higher levels of general anxiety than expected in the general population, 
whereas their level of depression and overall physical health were no different.  
 
Comparisons between familial LQTS and familial HCM revealed no difference 
between the groups with regard to general anxiety and depression, whereas heart-
focused anxiety was higher and physical health was poorer in the familial HCM 
group. 
 
Both heart-focused avoidance and fear about heart sensations had important roles in 
determining patients’ levels of general anxiety, depression and physical health. To 
what extent these individuals experienced heart-focused avoidance and fear about 
heart sensations, their reporting of general anxiety, depression, and physical health 
were related to varying degrees by these distinct symptoms of heart-focused anxiety. 
In addition, having a clinical diagnosis was of importance for their physical health, 
whereas a recent SCD in the family was related to higher levels of general anxiety 
and depression, regardless of disease status. 
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Paper III 
 
In a prospective design the three distinct symptoms of heart-focused anxiety 
(avoidance, attention, fear) were overall higher in patients with a clinical diagnosis of 
LQTS or HCM as compared to patients at genetic risk of LQTS or HCM, indicating 
that patients affected with a familial cardiac disorder have higher heart-focused 
anxiety.  
 
Predisposing factors for higher levels of heart-focused anxiety over time were a 
family history of sudden cardiac death in a close relative and uncertainty whether 
other relatives had undergone genetic testing. However, satisfaction with the 
procedural parts of genetic counseling was predictive of decreased levels of heart-
focused anxiety. The resources of greatest prognostic importance may be the way 
individuals perceive their general health and their self-efficacy expectations. 
 
The present findings indicate that patients undergoing genetic investigation and 
counseling for familial LQTS or familial HCM are vulnerable in both health-related 
and psychological domains before genetic counseling, and may benefit from a closer 
collaboration between the genetic counselor and the cardiologist addressing their 
experience of cardiac symptoms to a greater extent. 
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10. Clinical implications 
 
For the continuation of developing genetic counseling for these patients it is 
important to increase the understanding of the possibilities for improving quality of 
care. The patient-reported outcomes in this study allows for a better understanding of 
how this can be achieved.  
 
As stated previously in this thesis the main aim of genetic counseling is to help 
people to understand and adapt to the medical, psychological, and familial 
implications of genetic contribution to disease. The present study showed that one 
implication of living with the risk of serious arrhythmias and sudden cardiac death, in 
individuals with familial LQTS or familial HCM, was a poorer perceived health and a 
higher level of general anxiety than that of the general population. How may genetic 
investigation and counseling improve perceived general health and anxiety levels?  
 
Undergoing genetic investigation may in itself influence health perception and levels 
of general anxiety, for example by reassuring patients when they test negative for the 
family mutation (Aatre & Day, 2011), or by providing access to better follow-up and 
that feelings of uncertainty is removed for persons testing positive for the family 
mutation. Patients who already have a clinical diagnosis of LQTS or HCM may get 
more information about the etiology of the disorder, and learn more about the 
consequences for other relatives (Skrzynia, Demo, & Baxter, 2009). 
 
Individualizing the genetic counseling session to an even greater extent may also be a 
way to go. Today the protocol for pre-test counseling session of patients with familial 
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LQTS and familial HCM is more or less the same. Although the present study 
showed that these patient groups were similar with regards to general anxiety levels, 
the patients with a diagnosis of HCM demonstrated limitations in physical health 
domains compared to the general population, and were identified as the most 
vulnerable group with regards to health functioning. This indicates that the genetic 
counseling should adapt to this, using a more individual based approach to families 
with HCM, as they may have more concerns of health limitations, whereas LQTS 
patients may have other needs in their management of potential health threat.  
 
The genetic counselor may also try to educate the patients about their health and 
normalize emotions patients may have in relation to living with the risk. A study 
among individuals with panic disorder showed that individuals who perceived their 
health as poorer were more likely to experience anxiety, anger, depression and 
frustration (Gregor et al., 2005). This may indicate that by addressing general health 
perception the genetic counselor may also become aware of unresolved emotions of 
the patient. In the present sample poorer general health also predicted higher scores of 
cardio-protective behavior, heart-focused attention, and fear about heart sensations, 
which underlines the importance of addressing this patient-reported outcome.  
 
Before the patient is undergoing genetic investigation and counseling, heart-focused 
anxiety should be assessed. Being important in determining levels of general anxiety 
and depression, and physical health, this assessment will give the genetic counselor 
access to important information. Healthy persons that are heart-anxious are more 
likely to report panic and other anxiety disorders, more hypochondrial beliefs, 
physical symptoms, obsessive-compulsive concerns and negative affect (Eifert et al., 
1996). Our findings indicate that heart-focused anxiety may be a substantial problem 
among patients receiving genetic counseling for familial LQTS or familial HCM, 
most prevalent among clinically affected patients.  Intervention aimed at heart-
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focused anxiety may therefore increase health functioning and decrease general 
anxiety both in patients with and without cardiac disease (Eifert et al., 2000a; Eifert, 
2000b). Genetic investigation and counseling may be targeted as such intervention. 
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11. Implications for further research 
 
This study indicates that there are differences as well as similarities between HCM 
and LQTS patient groups.  
 
Big differences were found in health status. LQTS patients’ health status should be 
further investigated in bigger samples, and possibly with other patient-reported 
outcome measures that more can reflect the health issues in this population.  
 
In contrast to the differences in health status it was found that knowledge of a 
heightened genetic risk for serious arrhythmias and sudden cardiac death most likely 
is associated with anxiety pathology, regardless of disease status or familial LQTS or 
familial HCM. Since previous research has shown that general anxiety may decrease 
over time in patients at risk of familial LQTS (Hendriks et al., 2008), the role of 
genetic counseling should be investigated.  
 
Further, we have shown that specific anxiety for heart events may contribute to raise 
levels of general anxiety and depression. In addition to that heart-focused anxiety is 
related to poorer physical health. However, it still needs to be investigated what other 
variables may influence general anxiety in these patients.  
 
In addition, it is necessary to explore further if the high general anxiety before genetic 
counseling is due to the upcoming counseling session, or if the individuals by 
themselves are anxious because of living with this health threat and uncertainty. 
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In contrast to more general anxiety and distress levels that can be caused by many 
factors, heart-focused anxiety is the specific fear of cardiac-related stimuli and 
sensations because of their perceived negative consequences. Fearful responding to 
symptoms and information about risk may also have a profound negative effect on 
social and occupational life functioning (Eifert, 2000b), and this should be further 
explored in HCM and LQTS patients. 
The importance of understanding the association between perceived health and 
emotional vulnerability processes such as heart-focused anxiety has been pointed out, 
and suggests the need for further work investigating this cognitive variable as a 
possible risk factor for developing such problems (Yartz et al., 2005). Even more 
important in this patient group is the possible relationship between perceived health, 
heart-focused anxiety, and mortality. 
 
Finally, to what extent the present patient-reported outcomes may be different in 
individuals undergoing genetic investigation and counseling because of familial 
LQTS or familial HCM, from patients with other genetic diseases, or in healthy 
persons, should be further explored in future research.  
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